The research design is a prospective, randomized, controlled clinical trial in children to
study effect of aminophylline in preserving renal function in oncologic patient received
cisplatin either combined with other CMT or used alone. The participants in both groups will
receive standard protocol pre-cisplatin infusion which include hydration with 5%DNSS/2 with
KCL and MgSO4 IV infusion. In the treatment group, the participants will receive
aminophylline infusion in the first 24 hours along with cisplatin, followed by oral
aminophylline oral three times daily orally for 4 consecutive days post cisplatin. The
aminophylline serum level will be maintained at the therapeutic range 10-20 mg. The side
effect of aminophylline including nausea, vomiting and ECG will be monitored. The collected
data including urine volume, GFR (estimated by cystatin C-creatinine based equation and by
radiopharmaceutical-Tc DTPA), and renal tubular biomarker (urine B2 macroglobulin and urine
NGAL) will be collected at baseline before receiving cisplatin, 24 hours and 5 days post
cisplatin.